在复发的小细胞肺癌中使用temozolomide的结果:回顾性单中心分析
Sofie Dhaeyer1, Elise Missault1, Veerle Surmont2
1Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium.
Lung cancer (Amsterdam, Netherlands)
|April 25, 2025
概括
泰莫佐洛米德在治疗复发性小细胞肺癌 (SCLC) 中表现出适度的有效性. 这种口服化疗为托波特干提供了可行的替代方案,在现实世界SCLC患者护理中具有类似的响应率和较少的毒性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 广泛的小细胞肺癌 (SCLC) 预后不好,在初始化疗后经常复发.
- 目前的二线治疗方法,如托波特坎,具有有限的疗效和显著的毒性.
- 正在探索口服化剂Temozolomide作为复发性SCLC的替代药物.
研究的目的:
- 评估Temozolomide在复发性SCLC患者中的实际有效性和安全性.
- 为了比较temozolomide的结果与现有的二线治疗方法.
主要方法:
- 对47名重度预治疗的SCLC患者的回顾性分析,这些患者接受了泰莫索洛米德治疗 (250毫克/天,每28天1-5天).
- 收集的数据包括客观反应率 (ORR),疾病控制率 (DCR),无进展生存率 (PFS),总生存率 (OS) 和与治疗相关的不良事件 (TRAEs).
主要成果:
- 总体应答率 (ORR) 为14.9%,疾病控制率 (DCR) 为23.4%.
- 无进展生存时间 (mPFS) 中位数为1.7个月,总生存时间 (mOS) 中位数为3.2个月.
- 3-4级与治疗相关的不良事件 (TRAEs) 在34%的患者中发生.
结论:
- 泰莫佐洛米德在这个真实世界SCLC队列中表现出适度的临床活性.
- 它的可比响应率和较轻的毒性概况表明,它是治疗复发性SCLC的可行替代品.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...